Pub Date : 2023-04-20DOI: 10.31487/j.ijcst.2022.04.10
E. Matthews, M. Veeraputhiran, Jennifer Gernat, N. Yarlagadda, M. Bimali
Adults undergoing allogeneic hematopoietic stem-cell transplant (HSCT) experience progressive physical and psychosocial distress in early stages post-HSCT, including sleep-wake disturbance (SWD), psychological distress, and fatigue. We conducted a longitudinal feasibility study to determine severity/trajectory of SWDs and investigated relationships among actigraphic sleep parameters, sleepiness, insomnia severity, fear of cancer recurrence (FCR), anxiety, depression, and fatigue at 100 (T1), 150 (T2), and 180 days (T3) post-HSCT. Eight adults enrolled. Median total sleep time (TST) at T1–T3 days was adequate (7.24, 7.17, and 7.09 hours), but sleep efficiency (SE) was suboptimal (78.9%, 78.5%, 83.67%). Median Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI) scores indicated minimal drowsiness and subclinical insomnia at T1–T3. Median FCR Inventory (FCRI) scores indicate diminishing FCR over time. Median scores across time for anxiety (48.05, 50.2, and 44.1) and depression (44.9, 41, and 41) suggest moderate–mild distress with slight fluctuations. Surprisingly, fatigue scores increased from T1–T3 (46, 50.9, and 52.1). Increases in ISI and FCRI scores were associated with modest increases in anxiety. Findings suggest the need to evaluate and address sleep, psychological distress, and fatigue in HSCT recipients. Larger studies to confirm prevalence of SWD and association with psychological factors are warranted.
{"title":"Sleep-wake Disturbance following Allogeneic Hematopoietic Stem Cell Transplantation: Trajectory and Correlates","authors":"E. Matthews, M. Veeraputhiran, Jennifer Gernat, N. Yarlagadda, M. Bimali","doi":"10.31487/j.ijcst.2022.04.10","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.04.10","url":null,"abstract":"Adults undergoing allogeneic hematopoietic stem-cell transplant (HSCT) experience progressive physical and psychosocial distress in early stages post-HSCT, including sleep-wake disturbance (SWD), psychological distress, and fatigue. We conducted a longitudinal feasibility study to determine severity/trajectory of SWDs and investigated relationships among actigraphic sleep parameters, sleepiness, insomnia severity, fear of cancer recurrence (FCR), anxiety, depression, and fatigue at 100 (T1), 150 (T2), and 180 days (T3) post-HSCT. Eight adults enrolled. Median total sleep time (TST) at T1–T3 days was adequate (7.24, 7.17, and 7.09 hours), but sleep efficiency (SE) was suboptimal (78.9%, 78.5%, 83.67%). Median Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI) scores indicated minimal drowsiness and subclinical insomnia at T1–T3. Median FCR Inventory (FCRI) scores indicate diminishing FCR over time. Median scores across time for anxiety (48.05, 50.2, and 44.1) and depression (44.9, 41, and 41) suggest moderate–mild distress with slight fluctuations. Surprisingly, fatigue scores increased from T1–T3 (46, 50.9, and 52.1). Increases in ISI and FCRI scores were associated with modest increases in anxiety. Findings suggest the need to evaluate and address sleep, psychological distress, and fatigue in HSCT recipients. Larger studies to confirm prevalence of SWD and association with psychological factors are warranted.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"84 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82300775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-27DOI: 10.31487/j.ijcst.2023.01.02
Fernanda Tormen Korspalski, F. Macagnan, Émille Dalbem Paim, Vera Beatris Martins, Monalise Costa Batista Berbert
Dysphagia often occurs in the most severe cases of Covid-19 infection and has an impact on clinical outcomes and patients’ quality of life. Objective: This study aimed to describe the effects of intensive speech rehabilitation in cases of post-Covid-19 dysphagia in a hospital environment. Methods: This is a series of five patients admitted to a medical ward between May and August 2021. They were dysphagic, underwent orotracheal intubation and were submitted to evaluation and intensive speech therapy for five consecutive days. The intervention involved myofunctional exercises and in three cases electrical stimulation were also associated. The outcomes were: evolution of the Functional Oral Intake Scale (FOIS) and Penetration-Aspiration Scale (PAS) - according to videofluoroscopy - degree of dysphagia according to the Dysphagia Outcome and Severity Scale (DOSS) and improvement in quality of life (SWAL-QOL). Results: After therapy, one patient remained with severe dysphagia, two evolved to mild dysphagia, and two to functional deglutition. In four cases, there was an evolution of the PAS to level 1, showing reduction of aspiration episodes and laryngotracheal penetration, FOIS level 6 and improvement in the quality-of-life questionnaire scores. Conclusion: The therapy promoted an increase in the levels of oral intake, a reduction in the degree of severity of dysphagia and episodes of penetration and laryngotracheal aspiration, in addition to an improvement in the quality of life index in four of the five patients in this series.
{"title":"Intensive Dysphagia Rehabilitation Program Post Covid-19: Case Series Report","authors":"Fernanda Tormen Korspalski, F. Macagnan, Émille Dalbem Paim, Vera Beatris Martins, Monalise Costa Batista Berbert","doi":"10.31487/j.ijcst.2023.01.02","DOIUrl":"https://doi.org/10.31487/j.ijcst.2023.01.02","url":null,"abstract":"Dysphagia often occurs in the most severe cases of Covid-19 infection and has an impact on clinical outcomes and patients’ quality of life. \u0000Objective: This study aimed to describe the effects of intensive speech rehabilitation in cases of post-Covid-19 dysphagia in a hospital environment. \u0000Methods: This is a series of five patients admitted to a medical ward between May and August 2021. They were dysphagic, underwent orotracheal intubation and were submitted to evaluation and intensive speech therapy for five consecutive days. The intervention involved myofunctional exercises and in three cases electrical stimulation were also associated. The outcomes were: evolution of the Functional Oral Intake Scale (FOIS) and Penetration-Aspiration Scale (PAS) - according to videofluoroscopy - degree of dysphagia according to the Dysphagia Outcome and Severity Scale (DOSS) and improvement in quality of life (SWAL-QOL). \u0000Results: After therapy, one patient remained with severe dysphagia, two evolved to mild dysphagia, and two to functional deglutition. In four cases, there was an evolution of the PAS to level 1, showing reduction of aspiration episodes and laryngotracheal penetration, FOIS level 6 and improvement in the quality-of-life questionnaire scores. \u0000Conclusion: The therapy promoted an increase in the levels of oral intake, a reduction in the degree of severity of dysphagia and episodes of penetration and laryngotracheal aspiration, in addition to an improvement in the quality of life index in four of the five patients in this series.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75467042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-24DOI: 10.31487/j.ijcst.2022.04.04
Elana de Menezes Rossetto, Luísa Bello Gabriel, Bárbara Luísa Simonetti, Vera Beatris Martins, Monalise Costa Batista Berbert
Objective: To verify the effectiveness of a Brief and Intensive Dysphagia Therapy programme, in patients with head and neck cancer, during radio-chemotherapy. Study Design: This is a randomized clinical trial - pilot project with a random sample consisting of 11 patients divided into two groups: 7 in the intervention group, who received brief and intensive therapy and 4 in the control group, with weekly therapy. The assessment instruments used were tongue pressure measurement, mouth-opening measures, oral intake scale and quality of life questionnaire. Patients were evaluated before radio-chemotherapy, after 15 days of speech therapy and after radio-chemotherapy. Results: The intervention group presented higher values of lingual apex pressure (p = 0.00), mouth opening maintenance from the second evaluation (35.14 ± 16.82 mm) until the end of the radio-chemotherapy (35.29 p± 5.93 mm), greater oral intake functionality (p = 0.00) and improvement in overall aspects of quality of life questionnaire (p = 0.05) after completion of brief and intensive therapy and radio-chemotherapy. Conclusion: Brief and intensive therapy presented superior results in the maintenance and/or rehabilitation of the swallowing mechanism in patients with head and neck cancer undergoing radio-chemotherapy.
{"title":"Effects of Brief and Intensive Therapy for Dysphagia in Patients with Head and Neck Cancer during Radio-Chemotherapy: A Pilot Study","authors":"Elana de Menezes Rossetto, Luísa Bello Gabriel, Bárbara Luísa Simonetti, Vera Beatris Martins, Monalise Costa Batista Berbert","doi":"10.31487/j.ijcst.2022.04.04","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.04.04","url":null,"abstract":"Objective: To verify the effectiveness of a Brief and Intensive Dysphagia Therapy programme, in patients with head and neck cancer, during radio-chemotherapy. \u0000Study Design: This is a randomized clinical trial - pilot project with a random sample consisting of 11 patients divided into two groups: 7 in the intervention group, who received brief and intensive therapy and 4 in the control group, with weekly therapy. The assessment instruments used were tongue pressure measurement, mouth-opening measures, oral intake scale and quality of life questionnaire. Patients were evaluated before radio-chemotherapy, after 15 days of speech therapy and after radio-chemotherapy. \u0000Results: The intervention group presented higher values of lingual apex pressure (p = 0.00), mouth opening maintenance from the second evaluation (35.14 ± 16.82 mm) until the end of the radio-chemotherapy (35.29 p± 5.93 mm), greater oral intake functionality (p = 0.00) and improvement in overall aspects of quality of life questionnaire (p = 0.05) after completion of brief and intensive therapy and radio-chemotherapy. \u0000Conclusion: Brief and intensive therapy presented superior results in the maintenance and/or rehabilitation of the swallowing mechanism in patients with head and neck cancer undergoing radio-chemotherapy.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83882172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-18DOI: 10.31487/j.ijcst.2022.04.02
A. Avilés, S. Cleto
Objective: Assess if the addition of rituximab to a dose-dense chemotherapy regimen in patients with primary gastric diffuse large B-cell lymphoma (PGL) in early stage, but, associated with worse prognostic factors. Patients and Methods: Patients with pathological diagnosis of PGL and early stages, but, with elevated levels of beta 2 microglobulin and lactic dehydrogenase, age > 18 years age without upper limit, no gender differences, previously untreated, were recruit in an open label clinical trial, to received CHOP-14 (cyclophosphamide, vincristine, doxorubicin and prednisone, dose dense, every 14 days) and compare with patients that received R-CHOP14 (rituximab + CHOP-14). Results: Between March 2011 to December 2016, 141 patients were taken entry to the study: no statistical differences were observed in clinical and laboratory characteristics. Complete response (CR) was observed in 68 out of 72 (94.4%) patients in the CHOP-R14, and 67 out of 69 (95.1%) patients in the CHOP14 regimen. Actuarial curves at 5-years show that progression-free survival (PFS) was 89% (95%Confidence Interval (CI) in the CHOP-R14, that did not have statistical differences in the CHOP-14 arm: 92% (95%CI: 83% -97%) (p 0.887); the overall survival were: 90% (95% CI:86%-97%) and 93.4% (95% CI: 86% to 97%) (p 0,665). Toxicities were severe granulocytopenia and infection-related, but no dead were observed. Until now, late toxicities as acute leukemia, second neoplasms and cardiac damage has not been observed. Conclusion: The use of dose dense regimen (CHOP-14) confirm that is useful in the treatment of PGL associated to worse prognosis factors, the addition of rituximab did not show any benefit.
{"title":"Early Primary Gastric Lymphoma with Adverse Prognosis Factors. Is it Benefit Adding Rituximab to CHOP-14?","authors":"A. Avilés, S. Cleto","doi":"10.31487/j.ijcst.2022.04.02","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.04.02","url":null,"abstract":"Objective: Assess if the addition of rituximab to a dose-dense chemotherapy regimen in patients with primary gastric diffuse large B-cell lymphoma (PGL) in early stage, but, associated with worse prognostic factors.\u0000Patients and Methods: Patients with pathological diagnosis of PGL and early stages, but, with elevated levels of beta 2 microglobulin and lactic dehydrogenase, age > 18 years age without upper limit, no gender differences, previously untreated, were recruit in an open label clinical trial, to received CHOP-14 (cyclophosphamide, vincristine, doxorubicin and prednisone, dose dense, every 14 days) and compare with patients that received R-CHOP14 (rituximab + CHOP-14).\u0000Results: Between March 2011 to December 2016, 141 patients were taken entry to the study: no statistical differences were observed in clinical and laboratory characteristics. Complete response (CR) was observed in 68 out of 72 (94.4%) patients in the CHOP-R14, and 67 out of 69 (95.1%) patients in the CHOP14 regimen. Actuarial curves at 5-years show that progression-free survival (PFS) was 89% (95%Confidence Interval (CI) in the CHOP-R14, that did not have statistical differences in the CHOP-14 arm: 92% (95%CI: 83% -97%) (p 0.887); the overall survival were: 90% (95% CI:86%-97%) and 93.4% (95% CI: 86% to 97%) (p 0,665). Toxicities were severe granulocytopenia and infection-related, but no dead were observed. Until now, late toxicities as acute leukemia, second neoplasms and cardiac damage has not been observed.\u0000Conclusion: The use of dose dense regimen (CHOP-14) confirm that is useful in the treatment of PGL associated to worse prognosis factors, the addition of rituximab did not show any benefit.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90169799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-29DOI: 10.31487/j.ijcst.2022.03.02
Émille Dalbem Paim, Felipe de Oliveira Goulart, V. Martins, Fernanda Tormen Korspalski, F. Macagnan
Photobiomodulation (PBM) as a therapeutic technology is justified by the biochemical changes caused in the intracellular environment, such as increased production of adenosine triphosphate and activation of antioxidant enzymes, allowing early recovery and maintenance of the homeostasis and proper functioning. This case report aimed to describe the effect of orofacial myofunctional therapy associated or not with photobiomodulation in the rehabilitation of radio-induced trismus in 6 patients. Two intervention modalities were performed, with three patients undergoing OMT isolated and the other two subjects undergoing oral myofunctional therapy associated with photobiomodulation therapy (OMT+PBM). All participants completed the radiotherapy between 3 and 15 months before starting the trismus rehabilitation. The mouth opening was 21.00mm for the patients who underwent exclusive OMT and reached 30.25mm at the end of the rehabilitation (difference of 9.25mm), but for the other three patients submitted to OMT+PBM, it went from 8.4mm to 31.5mm (difference of 23,1mm). It was observed that patients who performed PBM+OMT had greater tolerance to the protocol exercises and less pain report. OMT+PBM was a good combination for trismus rehabilitation and could be considered in further randomized clinical trials.
{"title":"Orofacial Myofunctional Therapy with and without Photobiomodulation in the Rehabilitation of Radiation-Induced Trismus: Case Series","authors":"Émille Dalbem Paim, Felipe de Oliveira Goulart, V. Martins, Fernanda Tormen Korspalski, F. Macagnan","doi":"10.31487/j.ijcst.2022.03.02","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.03.02","url":null,"abstract":"Photobiomodulation (PBM) as a therapeutic technology is justified by the biochemical changes caused in the intracellular environment, such as increased production of adenosine triphosphate and activation of antioxidant enzymes, allowing early recovery and maintenance of the homeostasis and proper functioning. This case report aimed to describe the effect of orofacial myofunctional therapy associated or not with photobiomodulation in the rehabilitation of radio-induced trismus in 6 patients. Two intervention modalities were performed, with three patients undergoing OMT isolated and the other two subjects undergoing oral myofunctional therapy associated with photobiomodulation therapy (OMT+PBM). All participants completed the radiotherapy between 3 and 15 months before starting the trismus rehabilitation. The mouth opening was 21.00mm for the patients who underwent exclusive OMT and reached 30.25mm at the end of the rehabilitation (difference of 9.25mm), but for the other three patients submitted to OMT+PBM, it went from 8.4mm to 31.5mm (difference of 23,1mm). It was observed that patients who performed PBM+OMT had greater tolerance to the protocol exercises and less pain report. OMT+PBM was a good combination for trismus rehabilitation and could be considered in further randomized clinical trials.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86156348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.31487/j.ijcst.2022.04.03
M. Bektaş, M. Ay, M. Uyar, M. Kiliç, N. Koca, B. Ince
Background: Severe COVID-19 course is associated with higher inflammatory state (cytokine storm) due to the excessive release of pro-inflammatory cytokines. Some preliminary results showed higher disease severity as well as mortality in patients with COVID-19 accompanying cancer. In this study, we aimed to evaluate the high dose intravenous anakinra treatment response and outcome in patients with severe and critically ill COVID-19 accompanying cancer. Method: This observational retrospective study was carried out at a tertiary referral center between 01.09.2021 and 01.02.2022 in Turkey. The study population consisted of two groups as follows; the patients receiving high dose intravenous anakinra (anakinra group) and the patients treated with standard of care (SoC, control group). Anakinra was started in patients who did not respond to steroid therapy at least two days or concomitantly with steroids in patients with higher risk and/or critical illness at admission. Results: Data of 146 patients in anakinra and 114 patients in control group were analyzed. Median±interquartile range (IQR) patient age was 71 (25) years, duration of hospitalization were 11 (12) days in anakinra group and 65.5 (23) years and 9 (7.3) days in control group, respectively. Fifty-seven (39 %) and 68 (59.6 %) patients had severe, 89 (61 %) and 46 (40.4 %) had critical disease in anakinra and control group, respectively. Overall, ICU admission was in 58 (39.7 %) and 25 (22 %), intubation was in 52 (35.6 %) and 13 (11.4 %) patients, 54 (37 %) and 27 (23.7 %) patients died in anakinra and control group, respectively. Malignancy frequency was 11 % (n=16) in anakinra group and 7 % (n=8) in the control group. In survival analysis, significantly lower survival rate was observed in patients with malignancy than those without in control group (Log-Rank: p=0.002) and patients with malignancy in control group compared to anakinra group (Log-Rank: p=0.013); but did not differ between patients with and without malignancy in anakinra group (Log-Rank: p=0.9). Conclusion: In our study, mortality was higher in patients with malignancy compared to those without control but not in anakinra group and also higher in patients receiving anakinra compared to SoC. Our study indicates that intravenous high dose anakinra treatment is safe and effective in patients with COVID-19 associated cytokine storm accompanying cancer.
{"title":"Individualized High Dose Intravenous Anakinra Treatment is Safe and Effective in Patients with COVID-19 Associated Cytokine Storm Accompanying Cancer: A Retrospective Matched Study","authors":"M. Bektaş, M. Ay, M. Uyar, M. Kiliç, N. Koca, B. Ince","doi":"10.31487/j.ijcst.2022.04.03","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.04.03","url":null,"abstract":"Background: Severe COVID-19 course is associated with higher inflammatory state (cytokine storm) due to the excessive release of pro-inflammatory cytokines. Some preliminary results showed higher disease severity as well as mortality in patients with COVID-19 accompanying cancer. In this study, we aimed to evaluate the high dose intravenous anakinra treatment response and outcome in patients with severe and critically ill COVID-19 accompanying cancer.\u0000Method: This observational retrospective study was carried out at a tertiary referral center between 01.09.2021 and 01.02.2022 in Turkey. The study population consisted of two groups as follows; the patients receiving high dose intravenous anakinra (anakinra group) and the patients treated with standard of care (SoC, control group). Anakinra was started in patients who did not respond to steroid therapy at least two days or concomitantly with steroids in patients with higher risk and/or critical illness at admission.\u0000Results: Data of 146 patients in anakinra and 114 patients in control group were analyzed. Median±interquartile range (IQR) patient age was 71 (25) years, duration of hospitalization were 11 (12) days in anakinra group and 65.5 (23) years and 9 (7.3) days in control group, respectively. Fifty-seven (39 %) and 68 (59.6 %) patients had severe, 89 (61 %) and 46 (40.4 %) had critical disease in anakinra and control group, respectively. Overall, ICU admission was in 58 (39.7 %) and 25 (22 %), intubation was in 52 (35.6 %) and 13 (11.4 %) patients, 54 (37 %) and 27 (23.7 %) patients died in anakinra and control group, respectively. Malignancy frequency was 11 % (n=16) in anakinra group and 7 % (n=8) in the control group. In survival analysis, significantly lower survival rate was observed in patients with malignancy than those without in control group (Log-Rank: p=0.002) and patients with malignancy in control group compared to anakinra group (Log-Rank: p=0.013); but did not differ between patients with and without malignancy in anakinra group (Log-Rank: p=0.9).\u0000Conclusion: In our study, mortality was higher in patients with malignancy compared to those without control but not in anakinra group and also higher in patients receiving anakinra compared to SoC. Our study indicates that intravenous high dose anakinra treatment is safe and effective in patients with COVID-19 associated cytokine storm accompanying cancer.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88428107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-13DOI: 10.31487/j.ijcst.2022.03.01
M. Benakli, Redhouane Ahmed Nacer, Dina Ait Ouali, F. Mehdid, Rose Marie Hamladji
{"title":"Four Years Long-Term Follow-Up of Patient with Atypical Chronic Myeloid Leukemia Post Haploidentical Transplant with TBF Conditioning","authors":"M. Benakli, Redhouane Ahmed Nacer, Dina Ait Ouali, F. Mehdid, Rose Marie Hamladji","doi":"10.31487/j.ijcst.2022.03.01","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.03.01","url":null,"abstract":"<jats:p />","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79267781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-27DOI: 10.31487/j.ijcst.2022.02.02
Emery M. Cuellar, L. Kenney, M. Hughes
Glomus tumors (GTs) are mesenchymal tumors derived from modified smooth muscle cells of the glomus body. These tumors account for less than 2% of all soft tissue tumors, and of those less than 1% are malignant. A 35-year-old African American female presented with symptomatic iron deficiency anemia. On esophagogastroduodenoscopy, a 5 cm mass was seen partially obstructing the antrum and tissue biopsy was obtained. The biopsy showed low-grade epithelial mesenchymal neoplasm with features of a glomus tumor. A follow up computed tomography (CT) chest/abdomen/pelvis revealed a 5 cm relatively homogeneous solid mass in the gastric antrum, which appeared most similar to a gastrointestinal stromal tumor. During the planned distal gastrectomy with reconstruction, one hepatic metastasis was identified via intraoperative ultrasound and was confirmed by frozen section consultation to be the same histologic type as the antral mass. Pathologic and immunohistochemical findings were consistent with a malignant gastric glomus tumor with liver metastasis. Most GTs have a benign clinical course making the diagnosis and treatment of malignant GTs an ongoing challenge. The data on glomus tumors of the viscera is limited by the rarity of these tumors, with most of the known presentation and treatment gathered from case reports.
{"title":"Malignant Glomus Tumor of the Gastric Antrum with Liver Metastasis in a 35-year-old Female: A Case Report","authors":"Emery M. Cuellar, L. Kenney, M. Hughes","doi":"10.31487/j.ijcst.2022.02.02","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.02.02","url":null,"abstract":"Glomus tumors (GTs) are mesenchymal tumors derived from modified smooth muscle cells of the glomus body. These tumors account for less than 2% of all soft tissue tumors, and of those less than 1% are malignant. A 35-year-old African American female presented with symptomatic iron deficiency anemia. On esophagogastroduodenoscopy, a 5 cm mass was seen partially obstructing the antrum and tissue biopsy was obtained. The biopsy showed low-grade epithelial mesenchymal neoplasm with features of a glomus tumor. A follow up computed tomography (CT) chest/abdomen/pelvis revealed a 5 cm relatively homogeneous solid mass in the gastric antrum, which appeared most similar to a gastrointestinal stromal tumor. During the planned distal gastrectomy with reconstruction, one hepatic metastasis was identified via intraoperative ultrasound and was confirmed by frozen section consultation to be the same histologic type as the antral mass. Pathologic and immunohistochemical findings were consistent with a malignant gastric glomus tumor with liver metastasis. Most GTs have a benign clinical course making the diagnosis and treatment of malignant GTs an ongoing challenge. The data on glomus tumors of the viscera is limited by the rarity of these tumors, with most of the known presentation and treatment gathered from case reports.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"100 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81321204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-27DOI: 10.31487/j.ijcst.2022.02.01
Nayra Avina Padilla, K. Aviña-Padilla, M. Duarte Gutierrez, M. E. Miranda Flores, J. C. Rivas-Ferreira, D. R. Rivera Marquez, M. O. Guerrero Valle
Mantle Cell Lymphoma (MCL) is a lymphohematopoietic cancer of follicular origin and diffuse growth. It is a rare small B-cell lymphoma, with an incidence of 7-10% of all non-Hodgkin lymphomas, affecting adults (55-60 years), of which 80% are typically male. According to the World Health Organization guidelines, the diagnosis of MCL should be established based on morphological examination and immunophenotyping with detection of cyclin D1 resulting from the chromosomal translocation t(11;14)(q13;q32) of the CCND1 gene or SOX11 protein overexpression. Herein we present an infrequent clinical case of a female patient with MCL who presented erythroderma as a paraneoplastic cutaneous disorder. Moreover, we delved into the molecular insights of immune B-cell lymphocytic affections in this communication.
{"title":"Erythroderma as a Paraneoplastic Cutaneous Disorder in Mantle Cell Lymphoma: A Case Report and Literature Review of Molecular Insights into Physiopathology","authors":"Nayra Avina Padilla, K. Aviña-Padilla, M. Duarte Gutierrez, M. E. Miranda Flores, J. C. Rivas-Ferreira, D. R. Rivera Marquez, M. O. Guerrero Valle","doi":"10.31487/j.ijcst.2022.02.01","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.02.01","url":null,"abstract":"Mantle Cell Lymphoma (MCL) is a lymphohematopoietic cancer of follicular origin and diffuse growth. It is a rare small B-cell lymphoma, with an incidence of 7-10% of all non-Hodgkin lymphomas, affecting adults (55-60 years), of which 80% are typically male. According to the World Health Organization guidelines, the diagnosis of MCL should be established based on morphological examination and immunophenotyping with detection of cyclin D1 resulting from the chromosomal translocation t(11;14)(q13;q32) of the CCND1 gene or SOX11 protein overexpression. Herein we present an infrequent clinical case of a female patient with MCL who presented erythroderma as a paraneoplastic cutaneous disorder. Moreover, we delved into the molecular insights of immune B-cell lymphocytic affections in this communication.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78301621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-18DOI: 10.31487/j.ijcst.2022.01.01
Gang Zhao, Zhijie Wang
Introduction: Lesions in abdominal organs’ smooth muscles would obstruct organs from regular functions and lead to diseases. In regarding improve the precision of diagnosis with minimal suffering, electromyography (EMG) is developed to monitor smooth muscle activity and instruct diagnosis. Aim: This review aims to summarize and analyse past literature to discuss the present progress of EMG development and clinical application in monitoring abdominal organs’ smooth muscle diseases, focusing on the uterus, urinary system, and gastrointestinal tract. Results: EMG is a reliable tool to monitor smooth muscle activity based on the propagation of action potential with minimal lesions to the human body. Accuracy and the ability to automatically analyse signals are essentials for present EMG development, where some deficiencies can be complemented by other approaches. Significance: This review describes how EMG is currently applied in clinical studies to help diagnose and establish a better understanding of abdominal organs’ smooth muscle diseases. The findings will help future research workers to review the present advantages and disadvantages of EMG, and thus improve its accuracy and efficiency. The review also indicates the application of EMG can be extended onto other organs such as the gallbladder, which serves as a new direction to work with.
{"title":"A Review: Clinical Application of Electromyography in Abdominal Organs’ Smooth Muscle Diseases","authors":"Gang Zhao, Zhijie Wang","doi":"10.31487/j.ijcst.2022.01.01","DOIUrl":"https://doi.org/10.31487/j.ijcst.2022.01.01","url":null,"abstract":"Introduction: Lesions in abdominal organs’ smooth muscles would obstruct organs from regular functions and lead to diseases. In regarding improve the precision of diagnosis with minimal suffering, electromyography (EMG) is developed to monitor smooth muscle activity and instruct diagnosis.\u0000Aim: This review aims to summarize and analyse past literature to discuss the present progress of EMG development and clinical application in monitoring abdominal organs’ smooth muscle diseases, focusing on the uterus, urinary system, and gastrointestinal tract. \u0000Results: EMG is a reliable tool to monitor smooth muscle activity based on the propagation of action potential with minimal lesions to the human body. Accuracy and the ability to automatically analyse signals are essentials for present EMG development, where some deficiencies can be complemented by other approaches.\u0000Significance: This review describes how EMG is currently applied in clinical studies to help diagnose and establish a better understanding of abdominal organs’ smooth muscle diseases. The findings will help future research workers to review the present advantages and disadvantages of EMG, and thus improve its accuracy and efficiency. The review also indicates the application of EMG can be extended onto other organs such as the gallbladder, which serves as a new direction to work with.","PeriodicalId":13867,"journal":{"name":"International Journal of Cancer Science and Therapy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90873699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：